Ideas For Now-

I've sold that one Van. You need to keep up with the holdings!

Somebody please help explain VERI) 1st they get a US Gov contract ... now they get one with... China?
Veritone inks exclusive agreement with the South China Morning Post
Oct. 14, 2020 7:38 AM ET|About: Veritone, Inc. (VERI)|
Veritone (NASDAQ:VERI) licensing signs exclusive agreement with the South China Morning Post to expands its global news library.

The agreement gives Veritone the exclusive rights to license SCMP's archive and current video content to its clients in North America.

The deal is a significant milestone in Veritone's strategy to expand the global reach of its, AI-powered content library and enable content creators to engage with new and existing audiences through highly relevant content.
 
5G is a bit of a joke. Nevertheless carriers are ramping up the deals.. T Mobile is the only stock that was up yesterday and I think they may have the best deal.-

Let the promos begin...

The arrival of 5G iPhone 12 is anticipated to result in a robust upgrade cycle, triggering a battle in the carrier sphere, and a boon for iPhone maker Apple (NASDAQ:AAPL).

Both AT&T (NYSE:T) and Verizon (NYSE:VZ) are giving away models for free, provided that customers sign up for unlimited plans and trade in qualifying phones. Preorders start Friday.

While AT&T is offering the promotion to new and existing customers, Verizon is only offering free iPhones to newcomers. Existing Verizon customers can get a new iPhone for $15 a month for 24-months if they qualify.

T-Mobile US (NASDAQ:TMUS) is also in the promotion game. It's offering two iPhone 12 Pros for $100 each to new customers with trade-ins, as well as selling the new iPhone for half off with a trade-in.

Premarket: AAPL +1% to $122.30/share.
 
Well I figure if we are going to arbitration then it may as well be over a lot of money-- I'm in a lot of pain today. ) ) )

latest Email to land trust--

Update: I finished the fence along the line you layed out the second time. Unfortunately the adjustment to your former flag has caused me to have to transplant several wisteria-
The first time I just flipped the fence and allowed the plants to still entwine. I hope to god these plants make it. It became a difficult job. That was a really unfortunate extra 4 feet.

I smashed out one side of the Grotto and ruined it. You’ll be happy to know that. The rocks are bigger than I remembered. When I built it I had two strapping Australian brothers helping.
Today my shoulder & back hurts pretty bad.. I’m hesitant to go to the Dr because I do not wish to be prescribed opioids.
In the next few weekends I’ll move as much as I can. I have neurological condition called CMT. I feel this rushed process could endanger my health.

I will contact you again around Thanksgiving. My aim is to create a look of a “ ruin “ now, I’m not sure at the moment how to go about that.
 
Top Bio Idea Now May Be-- Gene splicer Intellia// 2nd write up--

Intellia Therapeutics initiated with an Overweight at Wells Fargo 08:40 NTLA Wells Fargo initiated coverage of Intellia Therapeutics with an Overweight rating and $38 price target. As genome editing players explore various niches in this new field, the firm believes Intellia Therapeutics has strategically positioned itself at the forefront of two areas with high potential for value creation. Intellia Therapeutics is among the first to explore liver-targeted in vivo genome editing, and Wells Fargo believes its approach, powered by lipid nanoparticle-based delivery and validated disease targets, is highly promising and scalable. Overall, the firm sees major opportunities in the company's pipeline, including nearer term in ATTR polyneuropathy, hereditary angioedema, and acute myeloid leukemia, as well as further upsides in ATTR cardiomyopathy and solid tumors.
 
Alright slightly more controversial but i have used stocks that use both heat and cold to treat cancers neither work very well... but the thought is always there that either extreme heat or cold can activate something...

B. Riley sees 200% upside in 'value vaccine play' Heat Biologics 08:19 HTBX B. Riley Securities analyst Justin Zelin initiated coverage of Heat Biologics with a Buy rating and $4 price target, which represents 200% potential upside. Heat has shown a "promising ability" to activate and stimulate T-cell responses, an important foundation of effective vaccines for cancer and infectious diseases, including SARS-CoV-2, Zelin tells investors in a research note. The analyst views Heat's Tcell activation data as an "important differentiating factor." Heat Biologics is a "value vaccine play," says Zelin.
 
Shift4 Payments upgraded to Neutral after pre-announcement at Compass Point 08:17 FOUR As previously reported, Compass Point analyst Mike Del Grosso upgraded Shift4 Payments to Neutral from Sell with a price target of $55, up from $35, following the company's pre-announcement of Q3 results that came along with its debt offering. In the near-term, consensus revenue estimates appear too conservative given recent disclosures, said Del Grosso, who still has longer-term concerns and believes "shares at current valuations reflect a near-perfect execution."
 
Geron shares have 100% potential upside, says B. Riley Securities 08:17 GERN B. Riley Securities transferred coverage of Geron to analyst Justin Zelin, who reiterates a Buy rating on the shares with a $4 price target. The analyst sees 100% upside potential in the shares and expects imetelstat to emerge as a "best-in-class" treatment of myelodysplastic syndrome. Further, imetelstat will likely demonstrate an overall survival benefit in myelofibrosis patients versus best available treatments and become the standard of care, Zelin tells investors in a research note. He sees peak sales for the drug of over $1B by 2030.
 
Everyone seems to love this company has anyone tried the mattress?

Purple Innovation price target raised to $33 from $26 at B. Riley Securities 08:11 PRPL B. Riley Securities analyst Susan Anderson raised the firm's price target on Purple Innovation to $33 from $26 and keeps a Buy rating on the shares. The analyst believes a post-COVID world will benefit the "healthy" remaining retailers given the significant shift to e-commerce, lower rent negotiations, competitor eliminations, and store rationalization opportunities. Anderson increased estimates to reflect recent checks and "strong" at home trends.
 
You must log in or register to reply here.
Back
Top